COLORADO SPRINGS, Colo.,
Dec. 15, 2014 /PRNewswire/
-- Cannabis Science, Inc. (OTCQB: CBIS), a U.S. Company
specializing in cannabis formulation-based drug development and
related consulting, congratulates the U.S. Congress for making
serious Medical Cannabis History by pulling this fiscal year's
funding for any DOJ actions that would stop legal state medical
cannabis programs and operations. The final bill passed the
House last week and the Senate over the weekend.
Please review:
Drug Policy Alliance: "HISTORIC VICTORY: Congress
Prohibits Justice Department from Undermining State Medical
Marijuana Laws"
NORML: "Federal Omnibus Includes Amendment to Prohibit
DOJ/DEA From Interfering With State Medical Marijuana"
The President announced his intention to sign the bill into law
in the coming days. Cannabis Science's recently announced
expansion within the California
medical cannabis market is even more compelling, and patients in
California and other legal medical
cannabis states can rest easy that they will not be denied needed
medicines.
"When President Obama signs this landmark bipartisan spending
bill, the federal government will have taken the most significant
stand to date to protect state medical cannabis programs from
federal interference. This is great news for Cannabis
Science, particularly in light of the Company's substantial new
investment in California
operations, and it is incredibly impactful for patients," said
Chad S. Johnson, Esq., Director,
COO, & General Counsel of Cannabis Science, Inc.
For more information, please see the following links:
Americans for Safe Access: "Patients Applaud Congressional
Restriction on Federal Medical Marijuana Enforcement in Omnibus
Budget Bill; Historic measure is similar to House amendment passed
earlier this year aimed at ending DOJ/DEA interference"
Smell the Truth: "Victory: Congress ends war on medical
marijuana"
The Huffington Post: "Congress Passes Historic Medical
Marijuana Protections in Spending Bill"
About Cannabis Science, Inc.
Cannabis Science, Inc.,
takes advantage of its unique understanding of metabolic processes
to provide novel treatment approaches to a number of illnesses for
which current treatments and understanding remain unsatisfactory.
Cannabinoids have an extensive history dating back thousands of
years, and currently, there are a growing number of peer-reviewed
scientific publications that document the underlying biochemical
pathways that cannabinoids modulate. The Company works with leading
experts in drug development, medicinal characterization, and
clinical research to develop, produce, and commercialize novel
therapeutic approaches for the treatment for illnesses caused by
infections as well as for age-related illness. Our initial focus is
on skin cancers and neurological conditions.
Forward-Looking Statements
This Press Release includes
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Act of
1934. A statement containing words such as "anticipate," "seek,"
intend," "believe," "estimate," "expect," "project," "plan," or
similar phrases may be deemed "forward-looking statements" within
the meaning of the Private Securities Litigation Reform Act of
1995. Some or all of the events or results anticipated by these
forward-looking statements may not occur. Factors that could cause
or contribute to such differences include the future U.S. and
global economies, the impact of competition, and the Company's
reliance on existing regulations regarding the use and development
of cannabis-based drugs. Cannabis Science, Inc., does not undertake
any duty nor does it intend to update the results of these
forward-looking statements.
Cannabis Science, Inc.
Raymond C. Dabney, Director,
President & CEO, Co-Founder
raymond@cannabisscience.com,
Tel: 1.310.650.3788
Chad S. Johnson, Esq., Director,
COO, & General Counsel
www.cannabisscience.com
info@cannabisscience.com
Tel: 1.888.777.0658
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/cannabis-science-cbis-congratulates-us-congress-for-historical-move-to-stop-the-department-of-justice-doj-impeding-legal-state-medical-cannabis-operations-perfect-timing-for-cbis-large-investment-in-california-300009510.html
SOURCE Cannabis Science, Inc.